2014 Trends in Strategic Outsourcing — Changes in the Qualities that Drive Outsourcing Partner Selection

Life Science Leader, January 2014 and Chemical Information Services, March 2014

The 2014 results from Nice Insight’s annual pharmaceutical and biotechnology outsourcing survey show positive news for both sides of outsourcing relationships. Just as there was an increase between 2012 and 2013 (+7% from 31% to 38%) in the percentage of respondents with an outsourcing expenditure between $10-$50 million, there was another 9% point increase in this expenditure bracket for the year ahead.

Slightly under half of all survey respondents (47%) stated they will spend between $10-$50M on outsourced projects in 2014. The respondent group who will spend fewer than $10M on outsourced projects continues to shrink, now comprising only 29% of respondents. One key difference in this increase in expenditure over the 2012-2013 change was that respondents indicated they would outsource a greater number of different services—up from 4.7 on average in 2013 to 6.4 in 2014. 

This year’s results show that as a whole, survey respondents prioritized the outsourcing drivers as follows: quality, reliability, regulatory, productivity, affordability and innovation. In the past three years, CROs and CMOs have taken notice that drug innovators—across all buyer groups — consistently prioritized quality and reliability in the top two positions.  It becomes clear that the contract organizations have made efforts to improve upon these customer perception measures, which have in turn been reflected in improved scores offered by sponsor organizations across several categories.  For example, the benchmark for quality increased among both CROs (up 1% from 71% to 72%) and CMOs (up 2% from 71% to 73%) from 2013 to 2014. 

One key difference in this increase in expenditure over the 2012-2013 change was that respondents indicated they would outsource a greater number of different services — up from 4.7 on average in 2013 to 6.4 in 2014.

CMOs fared better in terms of improving upon reliability, with a 1% point upturn, from 72% to 73%, while the CRO benchmark remained the same as last year at 72%. Interestingly, there was small decrease for the CRO regulatory benchmark, down 1% point from 74% to 73%; CMOs held steady at 74% for regulatory for both 2013 and 2014.  The small drop in averaged regulatory scores across all CROs coincided with a 5% downward shift in the percentage of respondents who will engage a CRO or CMO for regulatory support. These could be related, if sponsors were disappointed in with the regulatory knowledge their contractors possessed, it makes sense that they would be less inclined to acquire their assistance.  

ni_lsl_chart_0114.jpg

The prioritization of an outsourcing partner’s productivity has shifted each of the last three years, moving from fourth place in 2012 down to fifth in 2013 and back to fourth for 2014 — this year edging out affordability for the first time. When it comes to how sponsors evaluated CROs’ and CMOs’ performance on this measure, the data showed a 2% point decline in the CRO benchmark, down from 73% to 71%. However, CMOs on average maintained their scores, with the benchmark sticking at 73%. 
 
In light of increased outsourcing expenditure for 2014, it was not too unexpected for affordability to drop in rank — now holding fifth position, as compared to fourth in 2013 and third in 2012. Interestingly, at the same time this measure has dropped in priority among buyers of outsourced services, both CROs and CMOs affordability scores have climbed. The affordability benchmark for CROs increased 1% point from 69% to 70%, and among CMOs, the benchmark increased 3% points from 69% to 72%. 
 
There was some variation in ranking from the different buyer groups, for example, among emerging pharma respondents, affordability ranked third as compared to fifth across the other buyer groups.  Biotechs prioritized productivity slightly higher than the pharma groups or emerging biotechs, but perhaps the most notable difference was that emerging biotechs ranked innovation third, whereas the rest of the buyer groups ranked innovation sixth. The innovation benchmark for both CROs and CMOs was set at 72% in 2013. This was another area where CROs slipped in performance, with their averaged score at 71% in 2014. Yet, CMOs once again maintained their scores, with the benchmark staying at 72%.  

 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.